Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation

E. Eskilsson, GV. Rosland, KM. Talasila, S. Knappskog, O. Keunen, A. Sottoriva, S. Foerster, G. Solecki, T. Taxt, R. Jirik, S. Fritah, PN. Harter, K. Välk, J. Al Hossain, JV. Joseph, R. Jahedi, HS. Saed, SG. Piccirillo, I. Spiteri, L. Leiss, P....

. 2016 ; 18 (12) : 1644-1655. [pub] 20160610

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031667
E-zdroje Online Plný text

NLK Free Medical Journals od 1999 do Před 1 rokem
PubMed Central od 1999 do Před 1 rokem
Europe PubMed Central od 1999 do Před 1 rokem
Open Access Digital Library od 1999-01-01
Medline Complete (EBSCOhost) od 2004-01-01 do Před 1 rokem

Odkazy

PubMed 27286795
DOI 10.1093/neuonc/now113
Knihovny.cz E-zdroje

BACKGROUND: Amplification of the epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are among the most common genetic alterations in glioblastoma (GBM), the most frequent and most aggressive primary brain tumor. METHODS: In the present work, we analyzed the clonal evolution of these major EGFR aberrations in a small cohort of GBM patients using a unique surgical multisampling technique. Furthermore, we overexpressed both receptors separately and together in 2 patient-derived GBM stem cell lines (GSCs) to analyze their functions in vivo in orthotopic xenograft models. RESULTS: In human GBM biopsies, we identified EGFR amplification as an early event because EGFRvIII mutations emerge from intratumoral heterogeneity later in tumor development. To investigate the biological relevance of this distinct developmental pattern, we established experimental model systems. In these models, EGFR(+) tumor cells showed activation of classical downstream signaling pathways upon EGF stimulation and displayed enhanced invasive growth without evidence of angiogenesis in vivo. In contrast, EGFRvIII(+) tumors were driven by activation of the prototypical Src family kinase c-Src that promoted VEGF secretion leading to angiogenic tumor growth. CONCLUSIONS: The presented work shows that sequential EGFR amplification and EGFRvIII mutations might represent concerted evolutionary events that drive the aggressive nature of GBM by promoting invasion and angiogenesis via distinct signaling pathways. In particular, c-SRC may be an attractive therapeutic target for tumors harboring EGFRvIII as we identified this protein specifically mediating angiogenic tumor growth downstream of EGFRvIII.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031667
003      
CZ-PrNML
005      
20171124111218.0
007      
ta
008      
171025s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/neuonc/now113 $2 doi
035    __
$a (PubMed)27286795
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Eskilsson, Eskil $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
245    10
$a EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation / $c E. Eskilsson, GV. Rosland, KM. Talasila, S. Knappskog, O. Keunen, A. Sottoriva, S. Foerster, G. Solecki, T. Taxt, R. Jirik, S. Fritah, PN. Harter, K. Välk, J. Al Hossain, JV. Joseph, R. Jahedi, HS. Saed, SG. Piccirillo, I. Spiteri, L. Leiss, P. Euskirchen, G. Graziani, T. Daubon, M. Lund-Johansen, PØ. Enger, F. Winkler, CA. Ritter, SP. Niclou, C. Watts, R. Bjerkvig, H. Miletic,
520    9_
$a BACKGROUND: Amplification of the epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are among the most common genetic alterations in glioblastoma (GBM), the most frequent and most aggressive primary brain tumor. METHODS: In the present work, we analyzed the clonal evolution of these major EGFR aberrations in a small cohort of GBM patients using a unique surgical multisampling technique. Furthermore, we overexpressed both receptors separately and together in 2 patient-derived GBM stem cell lines (GSCs) to analyze their functions in vivo in orthotopic xenograft models. RESULTS: In human GBM biopsies, we identified EGFR amplification as an early event because EGFRvIII mutations emerge from intratumoral heterogeneity later in tumor development. To investigate the biological relevance of this distinct developmental pattern, we established experimental model systems. In these models, EGFR(+) tumor cells showed activation of classical downstream signaling pathways upon EGF stimulation and displayed enhanced invasive growth without evidence of angiogenesis in vivo. In contrast, EGFRvIII(+) tumors were driven by activation of the prototypical Src family kinase c-Src that promoted VEGF secretion leading to angiogenic tumor growth. CONCLUSIONS: The presented work shows that sequential EGFR amplification and EGFRvIII mutations might represent concerted evolutionary events that drive the aggressive nature of GBM by promoting invasion and angiogenesis via distinct signaling pathways. In particular, c-SRC may be an attractive therapeutic target for tumors harboring EGFRvIII as we identified this protein specifically mediating angiogenic tumor growth downstream of EGFRvIII.
650    _2
$a mozek $x diagnostické zobrazování $x patologie $7 D001921
650    _2
$a nádory mozku $x diagnostické zobrazování $x genetika $x metabolismus $x patologie $7 D001932
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a molekulární evoluce $7 D019143
650    _2
$a glioblastom $x diagnostické zobrazování $x genetika $x metabolismus $x patologie $7 D005909
650    _2
$a lidé $7 D006801
650    _2
$a multimodální zobrazování $7 D064847
650    _2
$a mutace $7 D009154
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a patologická angiogeneze $x metabolismus $7 D009389
650    _2
$a protoonkogenní proteiny pp60(c-src) $x metabolismus $7 D016392
650    _2
$a erbB receptory $x genetika $x metabolismus $7 D066246
650    _2
$a analýza přežití $7 D016019
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rosland, Gro V $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Talasila, Krishna M $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Knappskog, Stian $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Keunen, Olivier $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Sottoriva, Andrea $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Foerster, Sarah $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Solecki, Gergely $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Taxt, Torfinn $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Jirik, Radovan $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Fritah, Sabrina $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Harter, Patrick N $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Välk, Kristjan $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Al Hossain, Jubayer $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.). $7 gn_A_00003148
700    1_
$a Joseph, Justin V $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Jahedi, Roza $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Saed, Halala S $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Piccirillo, Sara G $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Spiteri, Inma $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Leiss, Lina $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Euskirchen, Philipp $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Graziani, Grazia $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Daubon, Thomas $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Lund-Johansen, Morten $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Enger, Per Øyvind $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Winkler, Frank $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Ritter, Christoph A $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Niclou, Simone P $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Watts, Colin $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Bjerkvig, Rolf $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
700    1_
$a Miletic, Hrvoje $u Department of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
773    0_
$w MED00193498 $t Neuro-oncology $x 1523-5866 $g Roč. 18, č. 12 (2016), s. 1644-1655
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27286795 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171124111340 $b ABA008
999    __
$a ok $b bmc $g 1255260 $s 992694
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 18 $c 12 $d 1644-1655 $e 20160610 $i 1523-5866 $m Neuro-oncology $n Neuro Oncol $x MED00193498
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace